SINOVAC BIOTECH LTD (SVA) Form 6-K — Aug 17, 2026
Sinovac reported unaudited first-half 2026 results via Form 6-K, with sales of $147.1 million, up 12.9% year over year, driven primarily by overseas revenue that rose 82.3% to $66.5 million, or 45.2% of total sales. The bottom line was mixed: total net loss narrowed to $91.4 million from $96.6 million and gross margin expanded to 65.0% from 62.5%, but net loss attributable to common shareholders widened to $60.2 million, or a loss of $0.84 per basic and diluted share, from $21.7 million, or $0.30 per share, as other income fell to $21.1 million from $161.9 million and income tax expense jumped to $21.6 million.
Key figures
- Revenue
- 147079000
- Total Debt
- $381.2 million ($148.0M short-term bank loans + $233.1M long-term bank loans)
- Revenue Yoy
- +12.9%
- Total Assets
- 8138788000
- Cash Position
- 998546000
- Gross margin
- 65.0% vs 62.5% prior year
- Rnd expenses
- 83153000
- Sga expenses
- 130914000
- Operating loss
- -$118.0 million vs -$258.3 million prior year
- Restricted cash
- 676287000
- Eps ex 2018 pipe
- -1
- Other income net
- 21102000
- Overseas revenue
- $66.5 million, +82.3% YoY, 45.2% of total sales
- Sipv sales growth
- +35.3%
- Income tax expense
- 21560000
- Weighted avg shares
- 71860702
- Dividends paid h1 2026
- $24.5 million to minority shareholders; $0.7 million to common shareholders
- Short term investments
- 5200955000
- Varicella vaccine sales
- $48.5 million, +62.4% YoY
- Cash and equivalents only
- 322259000
- Weighted avg shares ex 2018 pipe
- 60060702
- Dividend payable on balance sheet
- 657176000
- Net cash provided by investing activities
- 315060000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.